Novavax (NVAX) Operating Expenses (2010 - 2026)

Novavax's Operating Expenses history runs 17 years deep, the most recent figure standing at $154.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 2.52% year-over-year to $154.9 million; the TTM figure through Mar 2026 stood at $674.5 million (down 20.04% YoY), while the FY2025 annual figure was $670.7 million, down 27.97% from the prior year.
• Operating Expenses was $154.9 million for Q1 2026 at Novavax, up from $132.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $861.8 million in Q3 2022 to a low of $132.9 million in Q4 2025.
• Historically, Operating Expenses has averaged $349.0 million across 5 years, with a median of $254.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 77.32% in 2022, then sank 63.72% in 2023.
• A 5-year view of Operating Expenses shows it stood at $601.3 million in 2022, then retreated by 21.02% to $474.9 million in 2023, then slumped by 53.8% to $219.4 million in 2024, then sank by 39.42% to $132.9 million in 2025, then increased by 16.58% to $154.9 million in 2026.
• The last three Operating Expenses figures came in at $154.9 million (Q1 2026), $132.9 million (Q4 2025), and $248.5 million (Q3 2025), per Business Quant data.